Tarius SAC Tracker®
Background Analysis: US FDA Advisory Committee to Review Merck’s Cardiovascular Outcomes Trial for Vytorin (IMPROVE-IT Trial) – DEC 14, 2015 (EMDAC)
The SAC Tracker report for this meeting is only available for SAC Tracker Premium subscribers.
The SAC Tracker reports are available for FREE on this site until 10 days after the meeting is held.
To obtain unlimited access to SAC Tracker meeting reports back to 2010 and onwards, including the committee members' voting history, you must subscribe to the SAC Tracker Premium service.
METADATA: Sponsor: Merck Drug Name: ezetimibe; ezetimibe/simvastatin Drug Class: cholesterol absorption inhibitor; statin Indication: reduction of cardiovascular risk